There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Irhythm Technologies (IRTC – Research Report) and Zura Bio (ZURA – Research Report) with bullish sentiments.
Irhythm Technologies (IRTC)
Needham analyst David Saxon reiterated a Buy rating on Irhythm Technologies today and set a price target of $138.00. The company’s shares closed last Thursday at $110.88.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Irhythm Technologies with a $134.50 average price target.
See the top stocks recommended by analysts >>
Zura Bio (ZURA)
Zura Bio received a Buy rating and a $26.00 price target from Piper Sandler analyst Yasmeen Rahimi today. The company’s shares closed last Thursday at $4.36.
According to TipRanks.com, Rahimi is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zura Bio with a $21.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IRTC:
- iRhythm Technologies to Report First Quarter 2024 Financial Results on May 2, 2024
- Class Action Suit against iRhythm Technologies, Inc. (IRTC)
- iRhythm Announces Closing of $661.25 Million of 1.50% Convertible Senior Notes Due 2029, Including Full Exercise of Initial Purchasers’ $86.25 Million Option to Purchase Additional Notes
- iRhythm Prices Upsized Offering of $575.0 Million of 1.50% Convertible Senior Notes Due 2029
- iRhythm Announces Proposed Offering of $450.0 Million of Convertible Senior Notes
